Announcing A Permanent J-Code for Opdualag – 9/29/22

[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_column type=”4_4″ _builder_version=”4.19.4″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”et_body_layout”][et_pb_code _builder_version=”4.19.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”et_body_layout” sticky_enabled=”0″]Announcing A Permanent J-Code for a BMS Oncology Product J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg [/et_pb_code][/et_pb_column][/et_pb_row][/et_pb_section]